title: Human umbilical cord blood mononuclear cells decrease fibrosis and increase cardiac function in cardiomyopathy.
abstract: OBJECTIVE
  We investigated whether human umbilical cord blood mononuclear cells (HUCBC) can limit progressive cardiomyopathy in TO2 hamsters.
  
  
  METHODS
  A total of 22 TO2 1-month-old hamsters were treated with intramyocardial HUCBC, 4 x 10(6) in Isolyte, and 23 TO2 1-month-old hamsters were treated with intramyocardial Isolyte. A total of 16 1-month-old F1B hamsters served as controls and received intramyocardial Isolyte. Echocardiograms were performed on all hamsters prior to and monthly after treatment for 6 months. Heart tissues were then stained with hematoxylin and eosin, Masson's Trichrome and human leukocyte antibody.
  
  
  RESULTS
  In F1B hamsters, left ventricular fractional shortening (FS) and ejection fractions (EF) did not significantly decrease over 6 months. By contrast, in Isolyte-treated TO2 hamsters, FS decreased from 56.2 +/- 1.0% to 19.7 +/- 3.2% and EF decreased from 89.5 +/- 1.4% to 44.9 +/- 5.9% at 6 months (both p < 0.0001). The FS and EF in HUCBC-treated TO2 hamsters also progressively decreased over 6 months but the changes were more gradual, especially during the first month after HUCBC treatment when FS was 52.0 +/- 1.5% and EF was 89.5 +/- 1.4%, which was not significantly different from the FS and EF in the F1B hamsters. Moreover, in the HUCBC-treated hamsters, the FS and EF were 20-30% greater than FS and EF in Isolyte TO2 hamsters at 3 and 5 months (p < 0.01). In Isolyte-treated TO2 hamsters at 6-7 months, fibrosis involved 30.0 +/- 5.0% of left ventricle and 35.0 +/- 5.0% of septum. By contrast, in HUCBC-treated hamsters, fibrosis involved only 6.5 +/- 2.3% of the left ventricle and 6.3 +/- 1.8% of septum (p < 0.05). The average number of blood vessels per myocardial microscopic field in HUCBC-treated hearts was 53.5 +/- 0.8 versus 46.2 +/- 3.0 in Isolyte-treated TO2 hearts (p < 0.05).
  
  
  CONCLUSIONS
  HUCBC, when given as a single intramyocardial injection, can limit fibrosis and increase heart function over the short term in TO2 hamsters with cardiomyopathy.
authors.affiliation: Center for Cardiovascular Research, James A Haley Hospital/University of South Florida, 13000 Bruce B. Downs Blvd, 111, Tampa, Florida 33612, FL, USA. robert.henning@va.gov
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Henning
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Aufman
authors.forename: Masood
authors.initials: M
authors.lastname: Shariff
authors.forename: Darrell
authors.initials: D
authors.lastname: Sawmiller
authors.forename: Vincent
authors.initials: V
authors.lastname: DeLostia
authors.forename: Paul
authors.initials: P
authors.lastname: Sanberg
authors.forename: Michael
authors.initials: M
authors.lastname: Morgan
mesh_terms: D000818:Animals; D009202:Cardiomyopathies / Q000503:physiopathology / Q000628:therapy*; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D006224:Cricetinae; D005312:Fetal Blood / Q000166:cytology*; D005355:Fibrosis / Q000628:therapy*; D006321:Heart / Q000502:physiology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000502:physiology*; D013318:Stroke Volume; D014183:Transplantation, Heterologous; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000628:therapy*